The Bristol Myers Squibb subsidiary RayzeBio has opened a new 77,000-square-foot facility in Indianapolis, Indiana.

Bristol Myers Squibb has opened a $160M radiopharma facility in Indianapolis, scaling up production since acquiring RayzeBio ...

Bristol Myers Squibb has opened its radiopharmaceutical manufacturing facility in Indianapolis, which played a major role in ...

Bristol Myers Squibb is preparing to ship a new and possibly life-changing cancer treatment to patients across the world. The ...

Actithera’s radiopharma assets irreversibly bind to their targets, allowing for longer retention of the drug inside tumors.

Learn about June 2025’s top biotech deals, featuring major collaborations in small molecules, protein therapeutics, and ...

Radiopharmaceutical company RayzeBio, a wholly owned subsidiary of Bristol Myers Squibb, will license a therapeutic and diagnostic asset for prostate cancer from Philochem.

Philochem AG (Philochem), a wholly-owned subsidiary of the Philogen Group, and RayzeBio, Inc. (RayzeBio), a wholly-owned subsidiary of Bristol-Myers Squibb company, announced a definitive agreement ...

Radiopharmaceutical company RayzeBio, a wholly owned subsidiary of Bristol Myers Squibb, will license a therapeutic and diagnostic asset for prostate cancer from Philochem. The deal is worth $350 ...

After leading his previous company through a back-to-back IPO and M&A deal, the former chief executive of RayzeBio has raised $370 million to develop ...

PRINCETON, N.J., February 26, 2024--Bristol Myers Squibb (NYSE: BMY) announced today that it has successfully completed its acquisition of RayzeBio, Inc. (NASDAQ: RYZB). With the completion of the ...

Three biotech VC veterans, including one of the co-founders of radiopharma success story RayzeBio, are launching a new investment fund called Scion Life Sciences.